Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 11 2021
Historique:
received: 29 09 2020
revised: 04 03 2021
accepted: 10 09 2021
pubmed: 15 9 2021
medline: 12 1 2022
entrez: 14 9 2021
Statut: ppublish

Résumé

Oxidative phosphorylation (OXPHOS) is an active metabolic pathway in many cancers. RNA from pretreatment biopsies from patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy demonstrated that the top canonical pathway associated with worse outcome was higher expression of OXPHOS signature. IACS-10759, a novel inhibitor of OXPHOS, stabilized growth in multiple TNBC patient-derived xenografts (PDX). On gene expression profiling, all of the sensitive models displayed a basal-like 1 TNBC subtype. Expression of mitochondrial genes was significantly higher in sensitive PDXs. An

Identifiants

pubmed: 34518211
pii: 0008-5472.CAN-20-3242
doi: 10.1158/0008-5472.CAN-20-3242
pmc: PMC8563442
mid: NIHMS1741812
doi:

Substances chimiques

Anilides 0
IACS-010759 0
Oxadiazoles 0
Piperidines 0
Pyridines 0
cabozantinib 1C39JW444G

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5572-5581

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009599
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224065
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9
pubmed: 20080645
Cancer Cell. 2013 Jun 10;23(6):811-25
pubmed: 23764003
Theranostics. 2016 May 24;6(8):1205-19
pubmed: 27279912
Nat Med. 2018 Jul;24(7):1047-1057
pubmed: 29892061
Science. 1991 Oct 25;254(5031):568-71
pubmed: 1719633
J Clin Pathol. 2014 Aug;67(8):690-6
pubmed: 24904064
Cancer Metab. 2015 Oct 20;3:11
pubmed: 26500770
Sci Transl Med. 2019 Apr 17;11(488):
pubmed: 30996079
Sci Rep. 2019 Sep 10;9(1):13014
pubmed: 31506466
Sci Transl Med. 2019 May 8;11(491):
pubmed: 31068440
Clin Cancer Res. 2017 Nov 1;23(21):6468-6477
pubmed: 29093017
Cell Signal. 2020 Aug;72:109651
pubmed: 32335258
Breast Cancer Res. 2017 Aug 15;19(1):93
pubmed: 28810913
J Biomed Sci. 2018 Nov 12;25(1):80
pubmed: 30419905
Acta Pharmacol Sin. 2021 Jul;42(7):1180-1189
pubmed: 33149145
Mol Cancer Res. 2017 Jan;15(1):45-58
pubmed: 27671334
Cancer Cell. 2013 Mar 18;23(3):302-15
pubmed: 23477830
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
Ann Oncol. 2014 Jun;25(6):1122-7
pubmed: 24669015
Clin Cancer Res. 2013 Jan 1;19(1):279-90
pubmed: 23091115
Clin Cancer Res. 2019 Mar 15;25(6):1838-1850
pubmed: 30504427
PLoS Comput Biol. 2011 Oct;7(10):e1002240
pubmed: 22028643
Oncotarget. 2016 May 3;7(18):25113-24
pubmed: 26848621
Breast Cancer Res Treat. 2019 Apr;174(3):615-625
pubmed: 30607633
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Nat Commun. 2017 Jan 05;8:13732
pubmed: 28054552
Nat Med. 2018 Jul;24(7):1036-1046
pubmed: 29892070
Int J Biochem Cell Biol. 2013 Jan;45(1):90-8
pubmed: 22951354
PLoS One. 2015 Sep 01;10(9):e0136851
pubmed: 26325287
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Genome Biol. 2007;8(6):R107
pubmed: 17562024

Auteurs

Kurt W Evans (KW)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Erkan Yuca (E)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Stephen S Scott (SS)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ming Zhao (M)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Natalia Paez Arango (N)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Christian X Cruz Pico (CX)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Turcin Saridogan (T)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Maryam Shariati (M)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Caleb A Class (CA)

Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Christopher A Bristow (CA)

TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Christopher P Vellano (CP)

TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Xiaofeng Zheng (X)

Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ana Maria Gonzalez-Angulo (AM)

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Xiaoping Su (X)

Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Coya Tapia (C)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ken Chen (K)

The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Argun Akcakanat (A)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Bora Lim (B)

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Debu Tripathy (D)

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Timothy A Yap (TA)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Maria Emilia Di Francesco (MED)

Institute for Applied Cancer Science, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Giulio F Draetta (GF)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Philip Jones (P)

Institute for Applied Cancer Science, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Timothy P Heffernan (TP)

TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Joseph R Marszalek (JR)

TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funda Meric-Bernstam (F)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. fmeric@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH